Linda de Graaf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Linda de Graaf has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
W. L. Diemont
2 shared publicationsA. H. P. M. Brouwers
1 shared publicationEugène P van Puijenbroek
Head of Scientific Department Netherlands Pharmacovigilance Centre
1 shared publication- Eugène P. van Puijenbroek
Groningen Research Institute of Pharmacy, Pharmacotherapy, -Epidemiology and -Economics, University of Groningen, Groningen, The Netherlands
1 shared publication Mariette A. Fabius
Netherlands Pharmacovigilance Centre Lareb
1 shared publicationPaul Admiraal
Neurologist Gemini Hospital Den Helder, Netherlands
1 shared publication
Latest Publications
- 4 June 2004
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 58 (3) , 326-328
Is decreased libido associated with the use of HMG‐CoA‐reductase inhibitors?
Aims and methods: To describe patients with decreased libido during use of a HMG‐CoA‐reductase‐inhibitor, and to discuss causality and pharmacological hypotheses for this association by analysis of the adverse drug reactions (ADR) database of the Netherlands Pharmacovigilance Centre Lareb.Results: Eight patients were identified as having decreased libido during use of statins. In two of these cases testosterone levels were determined and appeared to be decreased.Conclusion: Decreased libido is a probable adverse drug reaction of HMG‐CoA‐reductase‐inhibitors and is reversible. The ADR may be caused by low serum testosterone levels, mainly due to intracellular cholesterol depletion.
- 4 June 2004
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 58 (3) , 326-328
Is decreased libido associated with the use of HMG‐CoA‐reductase inhibitors?
Aims and methods: To describe patients with decreased libido during use of a HMG‐CoA‐reductase‐inhibitor, and to discuss causality and pharmacological hypotheses for this association by analysis of the adverse drug reactions (ADR) database of the Netherlands Pharmacovigilance Centre Lareb.Results: Eight patients were identified as having decreased libido during use of statins. In two of these cases testosterone levels were determined and appeared to be decreased.Conclusion: Decreased libido is a probable adverse drug reaction of HMG‐CoA‐reductase‐inhibitors and is reversible. The ADR may be caused by low serum testosterone levels, mainly due to intracellular cholesterol depletion.
- 1 December 2003
- Published by Springer Nature in Pharmacy World & Science
- Vol. 25 (6) , 260-263
The Weber-curve pitfall: effects of a forced introduction on reporting rates and reported adverse reaction profiles
Background: In May 1999 Losec® MUPS (MUPS) were granted a marketing authorisation in the Netherlands, followed by the withdrawal of the Losec®capsules (capsules) in September 1999. Both formulations...
- 1 December 2003
- Published by Springer Nature in Pharmacy World & Science
- Vol. 25 (6) , 260-263
The Weber-curve pitfall: effects of a forced introduction on reporting rates and reported adverse reaction profiles
Background: In May 1999 Losec® MUPS (MUPS) were granted a marketing authorisation in the Netherlands, followed by the withdrawal of the Losec®capsules (capsules) in September 1999. Both formulations...
- 12 September 2003
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 56 (4) , 451-452
Chest pain during use of bupropion as an aid in smoking cessation
Aims To investigate the cause of chest pain during the use of bupropion as an aid to stop smoking.Methods The Netherlands Pharmacovigilance Centre received 22 reports of chest pain, associated with the use of bupropion as an aid to smoking cessation. Additional information about long‐term follow up was collected to analyze whether these complaints herald manifest cardiac disease.Results All but one patient recovered after withdrawal of bupropion. Seven patients were additionally investigated and in six of them, a cardiac cause could be excluded. During long‐term follow‐up, no coronary heart diseases were diagnosed.Conclusions These reports indicate that chest pain seems to be associated with the use of bupropion, but its origin remains unclear.
- 12 September 2003
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 56 (4) , 451-452
Chest pain during use of bupropion as an aid in smoking cessation
Aims To investigate the cause of chest pain during the use of bupropion as an aid to stop smoking.Methods The Netherlands Pharmacovigilance Centre received 22 reports of chest pain, associated with the use of bupropion as an aid to smoking cessation. Additional information about long‐term follow up was collected to analyze whether these complaints herald manifest cardiac disease.Results All but one patient recovered after withdrawal of bupropion. Seven patients were additionally investigated and in six of them, a cardiac cause could be excluded. During long‐term follow‐up, no coronary heart diseases were diagnosed.Conclusions These reports indicate that chest pain seems to be associated with the use of bupropion, but its origin remains unclear.
- 1 February 2003
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 37 (2) , 302-303
Ballism Associated with Bupropion Use
- 1 February 2003
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 37 (2) , 302-303
Ballism Associated with Bupropion Use